Efficacy of halobetasol and tazarotene lotion for plaque psoriasis utilizing IGAxBSA measurements

被引：0
|
作者：
Blauvelt, Andrew [1 ]
Green, Lawrence J. [2 ]
Bagel, Jerry [3 ]
Lin, Tina [4 ]
Martin, Gina [5 ]
Israel, Robert [5 ]
机构：
[1] Oregon Med Res Ctr, Portland, OR USA
[2] George Washington Univ, Sch Med, Dept Dermatol, Washington, DC USA
[3] Psoriasis Treatment Ctr Cent New Jersey, East Windsor, NJ USA
[4] Ortho Dermatol, Bridgewater, NJ USA
[5] Bausch Hlth, Bridgewater, NJ USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2019年 / 81卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
9785
引用
收藏
页码：AB201 / AB201
页数：1
相关论文
共 50 条
  • [1] CANADIAN EXPERT CONSENSUS ON USE OF HALOBETASOL PROPIONATE/TAZAROTENE LOTION FOR PLAQUE PSORIASIS
    Guenther, L.
    Prajapati, V
    Vender, R.
    Albrecht, L.
    Maari, C.
    Yanofsky, H.
    Gaudet, V
    Turchin, I
    VALUE IN HEALTH, 2023, 26 (06) : S407 - S407
  • [2] Canadian Expert Consensus on the Use of Halobetasol Propionate/Tazarotene Lotion for Plaque Psoriasis
    Guenther, Lyn
    Turchin, Irina
    Vender, Ron
    Albrecht, Lorne E.
    Maari, Catherine
    Yanofsky, Howard
    Prajapati, Vimal H.
    DERMATOLOGY AND THERAPY, 2024, 14 (07) : 1917 - 1928
  • [3] Impact of Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045% in the Management of Plaque Psoriasis in Adults
    Reddy, Vidhatha
    Myers, Bridget
    Yang, Eric J.
    Bhutani, Tina
    CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2020, 13 : 391 - 398
  • [4] Halobetasol Propionate and Tazarotene Combination Lotion 0.01%/0.045% for Psoriasis
    Nicholas D. Brownstone
    Tina Bhutani
    John Koo
    Current Dermatology Reports, 2021, 10 : 21 - 25
  • [5] Halobetasol Propionate and Tazarotene Combination Lotion 0.01%/0.045% for Psoriasis
    Brownstone, Nicholas D.
    Bhutani, Tina
    Koo, John
    CURRENT DERMATOLOGY REPORTS, 2021, 10 (01) : 21 - 25
  • [6] Long-Term Multiple Center Experience in Treating Plaque Psoriasis With Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion
    Abduelmula, Abrahim
    Gooderham, Melinda J.
    JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2023, 27 (03) : 293 - 294
  • [7] Efficacy of a Once-Daily Fixed Combination Halobetasol (0.01%) and Tazarotene (0.045%) Lotion in the Treatment of Localized Moderate-to-Severe Plaque Psoriasis
    Blauvelt, Andrew
    Green, Lawrence J.
    Lebwohl, Mark G.
    Yamauchi, Paul S.
    Lin, Tina
    Martin, Gina
    Pillai, Radhakrishnan
    JOURNAL OF DRUGS IN DERMATOLOGY, 2019, 18 (03) : 297 - 299
  • [8] Efficacy, Safety, and Tolerability of Halobetasol Propionate 0.01%-Tazarotene 0.045% Lotion for Moderate to Severe Plaque Psoriasis in the Hispanic Population: Post Hoc Analysis
    Alexis, Andrew F.
    Yamauchi, Paul S.
    Desai, Seemal R.
    Khaselev, Nelly
    Lin, Tina
    CUTIS, 2020, 105 (03): : 150 - +
  • [9] Impact of body mass index (BMI) on the efficacy and safety of halobetasol propionate 0.01%/tazarotene 0.045% (HP/TAZ) lotion in patients with plaque psoriasis
    Lebwohl, Mark G.
    Del Rosso, James Q.
    Alonso-Llamazares, Javier
    Lattouf, Mark
    Jacobson, Abby
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB130 - AB130
  • [10] Halobetasol and Tazarotene: Further Defining the Role of a Unique Fixed Combination Topical Lotion in Moderate-to-Severe Plaque Psoriasis
    Gold, Linda Stein
    Bagel, Jerry
    Lebwohl, Mark G.
    Lin, Tina
    Martin, Gina
    Pillai, Radhakrishnan
    JOURNAL OF DRUGS IN DERMATOLOGY, 2018, 17 (12) : 1290 - 1296
12345